To find out more information about Hib disease, vaccinations, and resources please go to the following links:
Centers for Disease Control and Prevention
Hib disease articles and links
Information for healthcare professionals and parents
Immunization Action Coalition
 |
Hib: Questions and Answers. Information about the disease and vaccines |
American Academy of Pediatrics (AAP)
American Academy of Family Physicians (AAFP)
Disclaimer
This Web site contains links to third-party Web sites on the Internet. These sites are not part of this GlaxoSmithKline Web site. The content and materials in these third-party Web sites are not produced or controlled by GlaxoSmithKline. Some of these third-party Web sites may refer to uses of our products that are not recommended by GlaxoSmithKline. GlaxoSmithKline makes no representation with respect to the content of any non-GlaxoSmithKline Web site. Patients should always consult with their physicians or healthcare professionals before using any prescription product.
Indication
HIBERIX is indicated for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib). HIBERIX is approved for use in children 15 months through 4 years of age (prior to fifth birthday).
Important Safety Information
- In clinical studies, adverse events in children receiving HIBERIX included pain and redness at the injection site, fever, fussiness, loss of appetite, and restlessness
- A severe allergic reaction (eg, anaphylaxis) after a previous dose of any Hib or tetanus toxoid-containing vaccine or any component of HIBERIX is a contraindication
- If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give HIBERIX should be based on potential benefits and risks
- Vaccination with HIBERIX may not protect 100% of susceptible individuals